NCT00113269View on ClinicalTrials.gov

Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

501

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Kidney Transplantation
Interventions
DRUG

basiliximab

IV

DRUG

rabbit anti-thymocyte globulin

IV

DRUG

tacrolimus

oral

DRUG

alemtuzumab

Intravenous (IV)

DRUG

mycophenolate mofetil

oral

DRUG

steroids

IV and/or oral

Trial Locations (29)

10029

New York

10032

New York

10532

Hawthorne

17105

Harrisburg

17822

Danville

20007

Washington D.C.

20010

Washington D.C.

27599

Chapel Hill

27710

Durham

29425

Charleston

33066

Tampa

33136

Miami

35294

Birmingham

45267

Cincinnati

53226

Milwaukee

53792

Madison

60611

Chicago

60612

Chicago

78229

San Antonio

80262

Denver

84132

Salt Lake City

90057

Los Angeles

92123

San Diego

94115

San Francisco

94143

San Francisco

94304

Palo Alto

97239

Portland

07039

Livingston

08901

New Brunswick

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT00113269 - Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients | Biotech Hunter | Biotech Hunter